Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

April 16, 2024

https://www.globenewswire.com/news-release/2024/04/16/2863544/0/en/Recursion-Appoints-Najat-Khan-PhD-as-Chief-R-D-Officer-and-Chief-Commercial-Officer.html

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq:RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion’s Board of Directors.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.